NASDAQ:MPLT

Maplight Therapeutics (MPLT) Stock Price, News & Analysis

Maplight Therapeutics logo
$5.96 -0.46 (-7.17%)
Closing price 03:59 PM Eastern
Extended Trading
$5.82 -0.14 (-2.27%)
As of 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Maplight Therapeutics Stock (NASDAQ:MPLT)

Advanced

Key Stats

Today's Range
$5.93
▼
$6.48
50-Day Range
$6.22
▼
$13.15
52-Week Range
$5.93
▼
$40.43
Volume
357,935 shs
Average Volume
460,122 shs
Market Capitalization
$318.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.50
Consensus Rating
Moderate Buy

Company Overview

MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for people with serious brain disorders. Its research focuses on treatments intended to address symptoms that can be difficult to manage with existing therapies.

The company’s investigational programs include ML-007 for schizophrenia and ML-004 for autism spectrum disorder. These candidates remain in development and are not approved medicines.

AI Generated. May Contain Errors.

Maplight Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

MPLT MarketRank™: 
3.06205283434 of 5 stars

Maplight Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 299th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Maplight Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 4 strong buy ratings, 9 buy ratings, 4 hold ratings, and 1 sell rating.

  • Upside Potential

    Maplight Therapeutics has a consensus price target of $29.50, representing about 395.0% upside from its current price of $5.96.

  • Amount of Analyst Coverage

    Maplight Therapeutics has only been the subject of 4 research reports in the past 90 days.

  • Read more about Maplight Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Maplight Therapeutics are expected to grow in the coming year, from ($4.74) to ($4.28) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Maplight Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Maplight Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Maplight Therapeutics has a P/B Ratio of 0.71. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.08% of the float of Maplight Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Maplight Therapeutics has a short interest ratio ("days to cover") of 10.31, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Maplight Therapeutics has recently decreased by 2.14%, indicating that investor sentiment is improving.
  • Dividend Yield

    Maplight Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Maplight Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Maplight Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Maplight Therapeutics this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for MPLT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Maplight Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $990,690.00 in company stock.

  • Percentage Held by Insiders

    3.80% of the stock of Maplight Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Maplight Therapeutics has minimal institutional ownership at this time.

  • Read more about Maplight Therapeutics' insider trading history.
Receive MPLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Maplight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MPLT Stock News Headlines

Beyond NVDA: The World’s Next #1 Company?
This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's. A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all.tc pixel
See More Headlines

MPLT Stock Analysis - Frequently Asked Questions

Maplight Therapeutics' stock was trading at $17.57 at the start of the year. Since then, MPLT shares have decreased by 66.1% and is now trading at $5.96.

Maplight Therapeutics, Inc. (NASDAQ:MPLT) announced its quarterly earnings results on Monday, November, 16th. The company reported ($0.97) earnings per share for the quarter, topping analysts' consensus estimates of ($1.22) by $0.25.

Maplight Therapeutics (MPLT) raised $252 million in an initial public offering (IPO) on the week of October 27th 2025. The company issued 14,800,000 shares at a price of $17.00 per share. Morgan Stanley, Jefferies, Leerink and Stifel served as the underwriters for the IPO.

Maplight Therapeutics' top institutional investors include Goldman Sachs Group Inc. (6.48%), Baker BROS. Advisors LP (2.10%), Marshall Wace LLP (1.10%) and Blue Owl Capital Holdings LP (1.00%). Insiders that own company stock include Christopher A Kroeger, Vishwas Setia, Robert C Malenka, Erin Pennock Foff, James Woodruff Lillie, Anatol Kreitzer, Jonathan Gillis, George Pavlov, Troy Cox and Timothy John Garnett.
View institutional ownership trends
.

Shares of MPLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/16/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MPLT
CIK
1770069
Fax
N/A
Employees
133
Year Founded
2018

Price Target and Rating

High Price Target
$46.00
Low Price Target
$13.00
Potential Upside/Downside
+395.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
($6.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$161.15 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-61.01%
Return on Assets
-57.81%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.53
Quick Ratio
16.52

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.34 per share
Price / Book
0.71

Miscellaneous

Outstanding Shares
53,480,000
Free Float
51,448,000
Market Cap
$318.74 million
Optionable
Optionable
Beta
N/A
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:MPLT) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners